In 546 adults with type 2 diabetes on titrated insulin glargine, oral orforglipron 12 mg and 36 mg cut HbA1c by 1.88% and 1.82% at 40 weeks vs 0.79% with placebo; weight fell up to 5.4%. GI adverse events were most common; no rise in hypoglycaemia.
RCTn = 546
Giorgino et al. Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial